MedTrace Logo

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

NCT05405439 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-11-03

No results posted yet for this study

Summary

This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

Conditions

Interventions

DRUG

TQB3823 tablets

TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).

DRUG

Abiraterone acetate tablets

Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）

DRUG

prednisone acetate tablets

Prednisone acetate tablet is a kind of glucocorticoids

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-25
Primary Completion
2023-07-19
Completion
2023-07-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05405439 on ClinicalTrials.gov